News

Image source: The Motley Fool.

Abbott Laboratories (NYSE: ABT)Q4 2023 Earnings CallJan 24, 2024, 9:00 a.m. ET

Operator

Continue reading

Source Fool.com

Shares of AT&T (NYSE: T) were falling today after strong phone subscriber additions were overshadowed by weak guidance for the new year.

After gaining yesterday in sympathy with a

It finally happened. About 10 years after being created, gene-editing specialist CRISPR Therapeutics (NASDAQ: CRSP) earned approval for its first therapy late last year. The treatment in question is

I can sum up Pfizer's (NYSE: PFE) stock performance over the last couple of years in one word (and only three letters): ugh. Shares of the big drugmaker have plunged more than 50% since the high set

Pfizer (NYSE: PFE) ended 2022 with a bang, delivering its highest level of revenue ever -- $100 billion -- thanks to its coronavirus vaccine and treatment. But the drop in demand for those products

Shares of AT&T (NYSE: T) were gaining today, even though there was no major news out on the stock. Instead, shares were rising along with rival Verizon (NYSE: VZ), which delivered strong earnings

Many stocks performed well last year, but Medtronic (NYSE: MDT) wasn't one of them. The medical device giant failed to keep pace with broader equities, partly because it was still dealing with

Shares of Coherus BioSciences (NASDAQ: CHRS) were sinking 8.6% lower as of 11:14 a.m. ET on Tuesday. The decline followed a nice pop for the stock on Monday after Coherus announced it was selling

Plug Power (NASDAQ: PLUG) stock is seeing explosive gains in Tuesday morning trading. The hydrogen-power company's share price was up by 19.7% as of 10:30 a.m. ET, according to data from S&P Global

With CRISPR Therapeutics (NASDAQ: CRSP) in the news thanks to its successful work in developing cutting-edge gene therapies, it's easy to assume that everything in the business is going swimmingly

Novavax (NASDAQ: NVAX) soared more than 2,700% early in the pandemic as investors bet on its ability to bring a coronavirus vaccine to market. The company followed through on that -- but not as

On Jan. 8, pharmaceutical giant Merck (NYSE: MRK) moved to acquire biotech Harpoon Therapeutics, (NASDAQ: HARP) for $680 million in cash. The point of the acquisition, which should close in the

Many stock analysts entered 2024 with the expectation that the year would mark a shift to value. After all, large-cap growth stocks had a stellar performance last year and many of them are now

Every portfolio should include a few monster stocks, or companies with huge market share and staying power, and products likely to drive growth for the long term. Healthcare is a great place to look

Sarepta Therapeutics (NASDAQ: SRPT) saw a lot of love from the market as the trading week kicked off on Monday. Investors pushed the stock almost 5% higher in price, a move due in no small part to

Shares of Coherus (NASDAQ: CHRS) rallied as much as 21.7% early Monday, then gave up its gains to trade up around 2.4% as of 2:40 p.m. ET. This occurred after the company announced an agreement to

Vertex Pharmaceuticals (NASDAQ: VRTX) has been one of the fastest-growing healthcare companies in recent years. Its products have made it a leader in cystic fibrosis (CF) treatment and it has been

The new year is here, and for many, it's a fresh opportunity to set financial goals and find fresh stocks to consider adding to a portfolio. The types of stocks you gravitate toward will broadly be

Right now marks an exciting moment for CRISPR Therapeutics (NASDAQ: CRSP) and its investors. The biotech company has reached three milestones in just a couple of months. First, back in November, the

Looking for stocks with explosive growth potential? The biotech industry is an excellent place to start. Small drugmakers often see their shares skyrocket following positive clinical or regulatory

The healthcare sector is home to many excellent, innovative corporations that have made many investors richer. However, no healthcare company has reached a market capitalization of $1 trillion

You've probably heard that bleeding-edge biotechs like Intellia Therapeutics (NASDAQ: NTLA) and CRISPR Therapeutics (NASDAQ: CRSP) are working hard to develop gene therapies to cure intractable

2023 was a great year to own stocks. The S&P 500 index of America's 500 biggest companies surged an above-average 17.5% last year, and after hitting a bit of a speed bump in the first week, has kept